The Vision Trial - Offering Real Hope for the Heavily Treated MCRPC Patient

[marnieg46]

As Fight Prostate Cancer (FPC) readers will likely have seen references to or read about the VISION trial either on the HU forum or from their own reading, the June 7 UroToday video with Oliver Sartor might be of interest and clarify some of the outcomes of this trial.

For those readers not familiar with this trial it involved a population of 817 metastatic castrate resistant cancer (mCRPC) who had been heavily treated and had received chemotherapy and AR directed therapy in the past. The patients were randomised to best standard of care therapy or lutetium – Lu-PSMA-617 (LuPSMA).

Key findings showed a significant improvement in overall survival with the addition of targeted radioligand therapy LuPSMA) to the standard of care in patients with progressive PSMA positive metastatic castration resistant cancer. At a median follow up of 20.9months the addition of LuPSMA led to a 40% reduction in the risk of death and a 4-month improvement in median OS versus SOC alone. The addition also led to a 5.3-month improvement in median radiographic progression free survival translating to a 60% reduction in the risk of progression of death.

Perhaps of interest to many readers will be the very encouraging comments by Sartor that “I believe that this is a strikingly positive trial. I believe that this agent now has a real proof of principle and we can look forward to additional trials with patients who are less heavily pretreated”. Sartor also noted the upcoming trials which also might be of some interest- PSMAfore trial targeting mCRPC without prior chemotherapy--see below:

healthunlocked.com/api/redi...

and the PSMAddition trial for castrate sensitive metastatic patients and also tests taking place using PSMA Lu 177 upfront with ADT and ARDT--see below:

clinicaltrials.gov/ct2/show...

BOTH TRIALS LOCATED IN THE USA, FRANCE, AND SPAIN --RECRUITING !!!

A final word of hope for those on this journey from Dr Sartor “I think we can anticipate that there could be additional positive trials moving forward. I think that is really important for us to be able to be hopeful for.” The link to the video below:

The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor

urotoday.com/video-lectures...

[NPfisherman]

From what Sartor said, I think the fact that despite being heavily pretreated with 1 or 2 taxane chemos plus abiraterone and enzalutamide, this therapy works for almost 50% of people getting a response. Also, the fact that 87% qualified for the treatment with positive PSMA lesions means that nearly everyone qualifies to be treated.

What is not to like here people?? For those struggling with MCRPC, sign up for the PSMAfore trial and have a good chance of a response as well as qualifying for the trial.

For those that are MHSPC with mets that do not resolve with abi or enza, sign up for the PSMAddition trial, and see if it doesn't resolve them. Generally, doing these newer treatments earlier gets better results. Look at abiraterone at STAMPEDE.

I like these podcasts with Alicia Morgans.

Thanks for posting, Marnie....

Fish

[Shooter1]

New treatment for another 4 mo. Looking for more in OS than 4 mo, but I can still dream.